Search results
Results from the WOW.Com Content Network
Skin and skin structure infections (SSSIs), also referred to as skin and soft tissue infections (SSTIs), [1] or acute bacterial skin and skin structure infections (ABSSSIs), [2] are infections of skin and associated soft tissues (such as loose connective tissue and mucous membranes).
A skin infection is an infection of the skin in humans and other animals, that can also affect the associated soft tissues such as loose connective tissue and mucous membranes. [ citation needed ] They comprise a category of infections termed skin and skin structure infections (SSSIs), or skin and soft tissue infections (SSTIs), [ 1 ] and acute ...
Impetigo is a contagious bacterial infection that involves the superficial skin. [2] The most common presentation is yellowish crusts on the face, arms, or legs. [2] Less commonly there may be large blisters which affect the groin or armpits. [2]
What it looks like: Athlete’s foot is a rash caused by a fungal infection of the skin. People typically develop a rash between the toes, and the skin becomes white, moist, and falls apart ...
Infection-related cutaneous conditions may be caused by bacteria, fungi, yeast, viruses, and/or parasites. Subcategories. ... Skin and skin structure infection;
[103] [127] GBS infections in adults include urinary tract infection, skin and soft-tissue infection (skin and skin structure infection) bacteremia without focus, osteomyelitis, meningitis and endocarditis. [3] GBS infection in adults can be serious, and mortality is higher among adults than among neonates. [103]
Tinea corporis is a fungal infection of the body, similar to other forms of tinea. Specifically, it is a type of dermatophytosis (or ringworm) that appears on the arms and legs, especially on glabrous skin; however, it may occur on any superficial part of the body.
Delafloxacin was approved by the FDA in June 2017, after it was noninferior to vancomycin plus aztreonam in two trials on 1042 patients with acute bacterial skin and skin structure infection. [10] New Drug Applications (NDA) for delafloxacin (Baxdela) 450 mg tablets and 300 mg injections were approved by the FDA in June 2017.